Company news

Theravance Biopharma, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Theravance Biopharma Announces First Subject Dosed in Phase 1 Study of TD-0903, in Development for the Treatment of Hospitalized Patients with Acute Lung Injury Caused by COVID-19

April 22, 2020

Theravance Biopharma Announces Peer-Reviewed Publication Highlighting TD-1473 Program in the Journal of Crohn's and Colitis

April 19, 2020

Theravance Biopharma Responds to COVID-19 Pandemic by Advancing TD-0903 to Treat Hospitalized Patients with Acute Lung Injury

April 8, 2020

Theravance Biopharma Announces Closing of Private Placement of $400 Million Non-Recourse Notes

March 1, 2020

Theravance Biopharma, Inc. Reports Fourth Quarter and Full-Year 2019 Financial Results and Provides Business Update

February 23, 2020

Theravance Biopharma Announces Presentations at Upcoming Investor Conferences

February 17, 2020

Theravance Biopharma to Report Fourth Quarter and Full Year 2019 Financial Results on February 24, 2020

February 12, 2020

Theravance Biopharma Announces Pricing of Public Offering of Ordinary Shares

February 10, 2020

Theravance Biopharma Announces Proposed Public Offering of Ordinary Shares

February 9, 2020

Theravance Biopharma Announces Presentation at the 38th Annual J.P. Morgan Healthcare Conference

January 6, 2020

Theravance Biopharma Announces Dosing of First Patient in Phase 2 Allergen Challenge Study of TD-8236, an Investigational, Lung-Selective, Inhaled Pan-Janus Kinase (JAK) Inhibitor for Inflammatory Lung Diseases

December 2, 2019

Theravance Biopharma to Present at Two Upcoming Investor Conferences

November 25, 2019

Theravance Biopharma to Present at the 2019 Credit Suisse Healthcare Conference

November 5, 2019

Theravance Biopharma, Inc. Reports Third Quarter 2019 Financial Results and Provides Business Update

November 4, 2019

Theravance Biopharma to Report Third Quarter 2019 Financial Results on November 5

October 28, 2019

Theravance Biopharma and Mylan to Present New Data on YUPELRI® (revefenacin) at the 2019 CHEST Annual Meeting

October 20, 2019

Theravance Biopharma Reports Positive Results from Phase 1 Clinical Trial of TD-8236, an Investigational, Lung-Selective, Inhaled Pan-Janus Kinase (JAK) Inhibitor for Inflammatory Lung Diseases

September 8, 2019

Theravance Biopharma, Inc. Reports Second Quarter 2019 Financial Results and Provides Business Update

July 30, 2019

Theravance Biopharma to Report Second Quarter 2019 Financial Results on July 31

July 24, 2019

Theravance Biopharma Reports New Data from Phase 2 Study of Ampreloxetine (TD-9855) in Oral Presentation at 32nd European Neurology Congress

July 21, 2019

Theravance Biopharma Reports New Data from Phase 2 Study of Ampreloxetine (TD-9855) in Presentation at 2019 International Association of Parkinsonism and Related Disorders (IAPRD) World Congress

June 17, 2019

Theravance Biopharma and Mylan Expand YUPELRI® (revefenacin) Development and Commercialization Agreement to Include China and Adjacent Territories

June 13, 2019

Theravance Biopharma Appoints Andrew Hindman as Senior Vice President and Chief Financial Officer

June 3, 2019

Theravance Biopharma to Present at the 18th Annual Needham Healthcare Conference

April 1, 2019

← Newer news releases

Calls

The 5 newest of 20 calls. Every call is listed under its year.

Decks

The 5 newest of 80 decks. Every deck is listed under its year.